DOV Out-Licenses Pain Candidate Bicifadine To XTL
This article was originally published in The Pink Sheet Daily
Executive Summary
XTL shifts bicifadine’s development away from “novel indications in acute and chronic pain” to neuropathic pain, firm says.
You may also be interested in...
Presidio Snaps Up XTL’s Early Hep C Program
NS5A inhibitor is valued at $4 million upfront, as much as $104 million more later.
Presidio Snaps Up XTL’s Early Hep C Program
NS5A inhibitor is valued at $4 million upfront, as much as $104 million more later.
DOV Reclaims Rights To Triple Reuptake Inhibitors From Merck
DOV says it will seek “broad partnership opportunities” to develop two norepinephrine, serotonin and dopamine reuptake inhibitors for depression.